Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Interpace, Now Diagnostics, Metabolon, and More

NEW YORK (360Dx) – Interpace Diagnostics Group announced this week that it has entered into an agreement with Acupath Laboratories through which Acupath will sell Interpace's ThyGenX and ThyraMIR tests. ThyGenX uses next-generation sequencing to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas. ThyraMIR is a microRNA gene expression classifier. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer, according to Interpace. Acupath will offer the tests as part of a menu of diagnostics for endocrinologists, endocrine surgeons, and other physicians focused on the diagnosis and treatment of thyroid cancer. Terms of the deal were not disclosed.

Now Diagnostics said that it has received the EC Design Examination Certificate, enabling the company to sell its AdexusDx hCG pregnancy test over the counter in the EU. The test can now be performed at a pharmacy or at home. It uses a finger stick method and lateral flow cartridge technology to test capillary blood and has greater than 99 percent sensitivity and specificity compared to a laboratory test, the company said. The test will be available in Europe in May.

Metabolon's joint metabolomics laboratory with Zhejiang Dian Diagnostics opened this week in HangZhou, China. Hangzhou Calibra Diagnostics, a majority-owned subsidiary of Zhejiang Dian, will exclusively offer Metabolon's metabolomics services and technology in China. Metabolon and Zhejiang Dian entered a joint laboratory licensing agreement in February 2017.

Immunovia announced this week that Nasdaq Stockholm's listing committee has approved the company's application for admission to trading its shares on the exchange. The approval is subject to customary conditions, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority. The first day of trading for the firm's stock is scheduled for April 3, and the last day of trading on Nasdaq First North, where it currently trades, is scheduled for March 29. The shares will continue to trade under the same ticker, IMMNOV.

CareDx said this week that it has completed the conversion of the full amount outstanding under the notes issued to JGB into CareDx common stock. During March 2018, the conversion of the full $26.3 million outstanding under the notes has resulted in the issuance of approximately 6.1 million shares of CareDx common stock to JGB. Following the conversion, there are no amounts outstanding to JGB, the firm said. Further, $9.4 million of the company's cash, which was restricted under the agreement with JGB, will become available for use. CareDx intends to consolidate its remaining $11.4 million debt obligation to Danske Bank and the Allenex former majority shareholders into one single term loan with Perceptive Advisors, which is scheduled to fund on April 13 whereupon the company can draw an initial tranche of either $15 million or $25 million.

QuantumDx said this week that it has been awarded ISO 13485:2016 certification. The company is currently developing the Q-POC point-of-care, portable molecular diagnostic analyzer for diagnosing a range of infectious diseases in less than 20 minutes, including tuberculosis, chlamydia, gonorrhea, and HPV.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.